Understanding the Complexities of Anticancer Drugs Resistance

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Drug Development".

Deadline for manuscript submissions: 30 September 2024 | Viewed by 307

Special Issue Editors


E-Mail Website
Guest Editor
Department of Precision Medicine, University of Campania 'Luigi Vanvitelli', Via L. De Crecchio 7, 80138 Naples, Italy
Interests: tumor microenvironment; epigenetics; immunotherapy; drug discovery; signal transduction
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Precision Medicine, University of Campania 'Luigi Vanvitelli', Via L. De Crecchio 7, 80138 Naples, Italy
Interests: epigenetics; molecular biology; cancer; RNA modifications; drug discovery; genomics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Anticancer drug resistance is a major challenge in cancer therapy and significantly impacts patient outcomes. Genetic mutations play a pivotal role in drug resistance. Cancer cells acquire mutations that alter their DNA, enabling them to evade the effects of anticancer drugs. These mutations can affect drug targets, drug metabolism, and DNA repair mechanisms, rendering the drugs ineffective. Furthermore, some mutations can activate alternative signaling pathways that bypass the drugs' intended targets. The tumor microenvironment can also contribute to drug resistance by providing a protective niche for cancer cells. Tumor cells interact with immune cells, fibroblasts, and blood vessels, creating a complex network. This interaction can lead to the secretion of factors that promote drug resistance, such as cytokines and growth factors. Additionally, the tumor microenvironment can create physical barriers, such as a dense extracellular matrix, limiting drug penetration into the tumor. Understanding the mechanisms of drug resistance can drive the development of effective cancer treatments, including new drugs, combination therapies, and personalized medicine approaches.  In this Special Issue of Cancers, we welcome original research articles or comprehensive reviews focusing on the complexities of anticancer drug resistance, including the mechanisms involved, the factors contributing to drug resistance, and the strategies to overcome drug resistance.

Dr. Mariarosaria Conte
Dr. Nunzio Del Gaudio
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers

This special issue is now open for submission.
Back to TopTop